Top-News

Nektar Therapeutics Aktie News

Aktie
WKN:  A419UB ISIN:  US6402683063 US-Symbol:  NKTR Branche:  Pharmazeutika Land:  USA
56,82 $
-0,87 $
-1,51%
48,801 € 18:37:06 Uhr
Depot/Watchlist
Marktkapitalisierung *
9,08 Mrd. €
Streubesitz
31,57%
KGV
-
Index-Zuordnung
-

Nektar Therapeutics News

30.11.25 - Der Aktionär
Nektar Therapeutics: "Marktpotenzial in Milliardenhöhe" – CBO im Exklusiv‑Interview (Teil 2)
30.11.25 - Der Aktionär
Nektar Therapeutics: "Unser Wirkmechanismus ist breit gefächert"– CBO im Exklusiv‑Interview (Teil 1)
08.11.25 - PR Newswire
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
New Data from REZOLVE-​AD Study of Rezpegaldesleukin Presented in Late-​Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting PR Newswire
06.11.25 - PR Newswire
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
Nektar Therapeutics Reports Third Quarter 2025 Financial Results PR Newswire
30.10.25 - PR Newswire
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London PR Newswire
28.10.25 - PR Newswire
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets PR Newswire
22.10.25 - PR Newswire
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Data from REZOLVE-​AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-​Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting PR Newswire
18.09.25 - PR Newswire
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
Nektar Presents New Data from REZOLVE-​AD Phase 2b Study for Rezpegaldesleukin in Late-​Breaker Oral Presentation at EADV 2025 PR Newswire
09.09.25 - PR Newswire
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
Nektar Announces REZOLVE-​AD Phase 2b Results for Rezpegaldesleukin Selected for Late-​Breaker Oral Presentation at EADV 2025 PR Newswire
03.09.25 - PR Newswire
Nektar Therapeutics to Participate in Two Investor Conferences in September
Nektar Therapeutics to Participate in Two Investor Conferences in September PR Newswire
14.08.25 - PR Newswire
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment PR Newswire
07.08.25 - PR Newswire
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
Nektar Therapeutics Reports Second Quarter 2025 Financial Results PR Newswire
31.07.25 - PR Newswire
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets PR Newswire
29.07.25 - PR Newswire
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-​to-Very Severe Alopecia Areata PR Newswire
02.07.25 - PR Newswire
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
01.07.25 - PR Newswire
Nektar Therapeutics Announces Pricing of $100 Million Public Offering
Nektar Therapeutics Announces Pricing of $100 Million Public Offering PR Newswire
30.06.25 - PR Newswire
Nektar Therapeutics Announces Proposed Public Offering
Nektar Therapeutics Announces Proposed Public Offering PR Newswire
24.06.25 - PR Newswire
REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis
REZOLVE-​AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-​to-Severe Atopic Dermatitis PR Newswire
23.06.25 - PR Newswire
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025
Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-​AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on ...
13.05.25 - PR Newswire
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +2,17%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »